Immune Globulin Subcutaneous (Human-Klhw) 20%

Introduction Overview

Generic Name

immune globulin subcutaneous (human-klhw) 20%

Brand Name

Xembify

Dosage Form

20% solution for subcutaneous infusion

Drug Class

Immune globulins

Pharmacokinetics

Absorption:
Xembify is administered subcutaneously, allowing gradual absorption of immunoglobulin G (IgG) antibodies into the systemic circulation via the subcutaneous tissue lymphatics. This route allows slower uptake compared to intravenous infusion, resulting in more stable serum IgG levels with less pronounced peaks and troughs. Absorption is influenced by the vascularity of the injection site, and frequent or multiple-site infusions (up to six sites simultaneously) optimize uptake. The use of an infusion pump facilitates controlled delivery rates ensuring consistent absorption kinetics. Clinical studies have demonstrated steady-state trough IgG levels are achieved after several weeks of dosing, especially in patients converted from intravenous preparations.

Distribution:
IgG distributes primarily within the intravascular and extravascular spaces, with a volume of distribution approximating plasma volume and some extension into extracellular fluids. Xembify's IgG molecules exhibit subclass distributions similar to normal human serum, permitting broad immunological activity within tissues. The distribution equilibrium includes passive diffusion into interstitial spaces and binding to Fc receptors on immune cells. Distribution is also affected by neonatal Fc receptor (FcRn) suggesting prolonged IgG half-life in circulation. The IgG preparation’s purity (≥98%) and the absence of preservatives reduce the risk of aggregation and aberrant tissue deposition.

Metabolism:
IgG administered via Xembify undergoes normal catabolic pathways similar to endogenous immunoglobulins. IgG molecules are metabolized primarily by reticuloendothelial system macrophages following Fc receptor-mediated endocytosis. This process recycles IgG through the FcRn pathway, extending half-life, typically averaging 21 to 28 days. The metabolism does not produce active metabolites but results in amino acid recycling. Use of highly purified IgG minimizes potential immunogenic fragments, which can otherwise contribute to adverse immune responses.

Elimination:
The clearance of IgG from the circulation follows first-order kinetics mediated by proteolytic catabolism, primarily in endothelial and macrophage lysosomes. Renal elimination of intact IgG is negligible due to high molecular weight (~150 kDa). Elimination half-life is influenced by patient pathological states, including infections or immune disorders. Long-term subcutaneous administration provides steady IgG levels with minimal systemic accumulation risk. The pharmacokinetic profile supports flexible dosing regimens ranging from daily to biweekly, facilitating individualization based on clinical response and tolerability.

Dosage Forms

Available Dosage Forms:
Xembify is formulated as a sterile, ready-to-use 20% (200 mg/mL) solution for subcutaneous infusion. It is supplied in prefilled infusion devices or vials suitable for use with subcutaneous infusion pumps. The preparation is preservative-free, contains 18%-22% IgG protein, with excipients including 0.16 M to 0.26 M glycine and 10-40 mcg/mL polysorbate 80, ensuring stability and tolerability.

Dosages for Adults and Adolescents:
The dosing regimen is individualized based on prior IgG treatment and serum IgG trough levels. For patients transitioning from intravenous immune globulin (IVIG), the initial weekly dose is calculated by converting the previous IVIG dose with a dose adjustment factor of 1.37, divided into weekly or biweekly infusions. Treatment-naïve patients receive a loading dose of 150 mg/kg/day subcutaneously for 5 consecutive days, followed by maintenance dosing of 150 mg/kg weekly. Maximum per infusion site volume is 25 mL, with controlled infusion rates (≤35 mL/hr/site for adults and children ≥10 years; ≤25 mL/hr/site for children 2 to <10 years).

Specific Patient Populations:
Xembify is approved for patients aged 2 years and older with primary humoral immunodeficiencies. Dose adjustments are necessary in pediatric patients considering body weight and infusion tolerability. Elderly patients require careful monitoring for thrombotic events and renal function. Patients with pre-existing renal impairment, a history of thrombosis, or receiving concomitant nephrotoxic drugs require individualized dosing and observation. The subcutaneous route allows self-administration, facilitating outpatient management across diverse populations.

Administration Guidelines:
Xembify can be infused at intervals ranging from daily up to every two weeks. Up to six infusion sites can be used simultaneously, maintaining at least 2 inches apart from injection sites to avoid overlapping tissue effects. Sites recommended include upper outer arms, abdomen (excluding areas within 2 inches of the navel), and thighs, avoiding bony prominences, visible veins, scars, or inflamed areas. Patients are trained to self-administer with an infusion pump under healthcare provider supervision.

Mechanism Of Action

Xembify functions as a replacement therapy delivering exogenous immunoglobulin G (IgG) antibodies to patients with primary humoral immunodeficiencies (PI) who have impaired or absent endogenous antibody production. The primary molecular mechanism involves the passive provision of a broad spectrum of polyclonal IgG antibodies derived from pooled human plasma, allowing immediate immunological protection.

At the cellular level, administered IgG antibodies bind to and neutralize pathogens such as bacteria, viruses, and their toxins, thereby preventing their adherence and invasion of host tissues. Additionally, IgG interacts with various Fc gamma receptors (FcγRs) on immune effector cells, modulating immune responses by enhancing phagocytosis, antibody-dependent cell-mediated cytotoxicity, and regulating inflammatory pathways. This immune modulation helps reduce infection susceptibility and may downregulate aberrant immune responses.

Biochemically, Xembify's IgG molecules engage complement system components, activating the classical pathway which leads to the lysis and clearance of pathogens. The polyspecific nature of IgG antibodies provides recognition against a vast array of antigens, enhancing host defense. Importantly, the high purity and subclass distribution in Xembify mirror that of normal serum IgG, optimizing its functional heterogeneity and half-life.

Clinical implications include improved infection management and decreased frequency of serious infections in PI patients. Compared to intravenous immunoglobulin (IVIG) therapies, subcutaneous administration via Xembify offers more stable IgG serum levels, decreased systemic adverse reactions, and greater convenience through self-administration. Research evidence from clinical trials demonstrates effective IgG trough levels with individualized dosing and safety in both treatment-naïve and previously treated patients. This advances immune replacement therapy by enhancing quality of life and reducing hospital visits for immunoglobulin infusions.

Pharmacological Actions

Replenishes deficient immunoglobulin G (IgG) antibodies in patients with primary humoral immunodeficiencies.
Provides broad-spectrum passive immunity against bacterial, viral, parasitic, and mycoplasmal agents and their toxins.
Modulates immune system activity by interacting with immune cells via Fc gamma receptors, enhancing phagocytosis and cytotoxic functions.
Activates classical complement pathway inducing pathogen lysis and clearance.
Reduces frequency and severity of infections in immunodeficient patients by restoring humoral immunity.
Exhibits immunomodulatory effects potentially beneficial in autoimmune and inflammatory conditions (investigational).
Offers stable serum IgG levels via subcutaneous infusion, minimizing systemic adverse events.
Enables self-administration, improving patient autonomy and reducing healthcare resource utilization.
Non-pyrogenic and preservative-free formulation reduces risk of infusion-related hypersensitivity.
Long half-life due to Fc neonatal receptor (FcRn) mediated recycling prolongs therapeutic effect.
Maintains IgG subclass distribution consistent with normal human serum for comprehensive immune protection.
Delivers immunoglobulin with >98% purity and low IgA content to minimize hypersensitivity risk.
Bypasses gastrointestinal degradation, ensuring bioavailability of functional IgG.
No significant drug metabolism interference, allowing co-administration with multiple medications.

Therapeutic Or Clinical Uses

Treatment of primary humoral immunodeficiencies including congenital agammaglobulinemia.
Management of common variable immunodeficiency (CVID) by providing essential IgG antibodies.
Replacement therapy in X-linked agammaglobulinemia to prevent serious infections.
Supportive therapy in Wiskott-Aldrich syndrome with associated immunodeficiency.
Therapeutic option for severe combined immunodeficiencies involving antibody deficiency.
Prevention of recurrent bacterial infections in patients with antibody production deficits.
Use in patients with primary immunodeficiency who are treatment-naïve to immunoglobulin therapy.
Bridge therapy for patients transitioning from intravenous to subcutaneous immunoglobulin administration.
Adjunct therapy to reduce infection-related complications in chronic immunodeficiency states.
Facilitates outpatient management through self-administration protocols.
Provides steady therapeutic IgG serum levels with flexible dosing intervals from daily to biweekly.
Considered in patients intolerant to intravenous immunoglobulin due to infusion reactions.
Used to maintain immunoglobulin trough levels above protective thresholds.
Administered in both pediatric (≥2 years) and adult patient populations with immunodeficiencies.
Applicable for patients with contraindications to other immunoglobulin formulations.

Side Or Adverse Effects

Injection site reactions including redness, pain, swelling, bruising, itching, firmness, or nodules.
Respiratory symptoms such as cough may occur post-infusion.
Gastrointestinal disturbances including diarrhea have been reported.
Potential for serious allergic reactions including anaphylaxis, characterized by hives, swelling of mouth or throat, wheezing, or dizziness.
Risk of thrombosis (blood clots), especially in older adults or patients with predisposing factors.
Aseptic meningitis syndrome presenting with headache, nausea, vomiting, stiff neck, fever, photophobia, or fatigue.
Renal dysfunction including acute kidney injury; signs include swelling, rapid weight gain, and decreased urination.
Liver injury indicated by abnormal liver function tests, yellowing of skin or eyes, and dark urine.
Local infusion site infections or irritation due to improper technique or repeated administration.
Headache and fatigue linked to immune activation.
Fever or chills occurring shortly after infusion in some patients.
Hypotension or hypertension as part of infusion-related systemic reactions.
Rare transmission risk of infectious agents despite rigorous plasma screening.
Possible formation of nodules or firmness at infusion sites with repeated administration.
Report any unusual or persistent side effects to healthcare providers immediately.

Precautions

Perform thorough patient history screening for prior allergic reactions to immunoglobulins or blood products.
Monitor patients with IgA deficiency carefully due to increased risk of anaphylactic reactions.
Assess risk factors for thrombosis including age, cardiovascular history, and coexisting conditions prior to therapy.
Evaluate renal function prior to and periodically during treatment to detect kidney injury early.
Avoid use in patients with hyperprolinemia due to potential metabolic complications.
Educate patients on proper infusion techniques and site rotation to minimize local adverse reactions.
Use caution in patients on estrogen therapy, with long-term immobilization, or central venous catheters due to thrombotic risks.
Inform patients that live virus vaccines may be less effective during treatment with Xembify.
Ensure hydration status is adequate before infusion to maintain renal perfusion.
Monitor for signs of aseptic meningitis syndrome post-infusion, especially in high-dose use.
Adjust dosing regimens based on serum IgG trough levels and clinical response.
Be aware of potential interference with serological testing due to passively administered antibodies.
Pregnancy and breastfeeding decisions should involve careful risk-benefit analysis with clinician guidance.
Do not mix Xembify with other medications or infusion solutions to avoid incompatibilities.
Maintain strict aseptic technique during preparation and administration to reduce infection risk.

Warnings

Black Box Warning for risk of thrombosis (blood clots) associated with immune globulin therapy.
Seek immediate medical attention if symptoms of thrombosis such as unilateral limb swelling, pain, or chest pain occur.
Potential for severe allergic or anaphylactic reactions; contraindicated in patients with known hypersensitivity.
Aseptic meningitis syndrome risk necessitates vigilance for neurological symptoms shortly after infusion.
Renal dysfunction including acute kidney injury can occur, particularly in patients with predisposing conditions.
May carry risk of transmitting infectious agents despite thorough plasma screening and viral inactivation.
Use caution in patients with cardiovascular or cerebrovascular disease due to increased clotting risk.
Prolonged immobilization or use of hormone therapies may heighten thrombotic risk during therapy.
Do not administer intravenously; limited to subcutaneous infusion.
Limited data available on long-term safety in treatment-naïve and pediatric patients; monitor closely.
Discontinue infusion immediately upon signs of anaphylaxis or severe adverse reactions.
Patients should be made aware of potential vaccine efficacy reduction during treatment courses.
Ensure proper dose calculation and administration protocols to avoid overdose and toxicity.
Monitor liver enzyme levels when clinically indicated given possible hepatotoxicity.
Avoid use in patients with IgA antibodies to prevent severe hypersensitivity.

Contraindication

Known hypersensitivity to Xembify or other immune globulin products.
Patients with immune globulin A (IgA) deficiency who have antibodies to IgA due to risk of anaphylaxis.
Individuals with a history of severe allergic reaction to polysorbate 80, an inactive ingredient in Xembify.
Patients diagnosed with hyperprolinemia (elevated proline levels in blood).
In patients with thromboembolic disorders unless benefits outweigh risks after careful assessment.
History of severe adverse reactions to any blood or blood-derived products.
Contraindicated for intravenous administration; subcutaneous use only.
Use contraindicated if active severe renal impairment where immunoglobulin infusion may exacerbate condition.
Patients with known hypersensitivity to glycine or any excipients in formulation.
Contraindicated in acute severe infections without concurrent antibiotic therapy.
Those with hypersensitivity reactions during prior immunoglobulin replacement therapy.
Patients with untreated sepsis not adequately managed before immunoglobulin administration.
Known hypersensitivity to human plasma proteins in general.
Active thrombophlebitis or hypercoagulable states without appropriate prophylaxis.
Contraindicated in pediatric patients under 2 years due to lack of safety data.

Drug Interactions

Xembify may interfere with the immune response to live virus vaccines such as measles, mumps, rubella (MMR), and varicella vaccines by neutralizing vaccine virus and diminishing efficacy.
Concomitant use with estrogens (e.g., birth control pills or hormone replacement therapy) may increase the risk of thrombosis.
Potential interaction with nephrotoxic medications increasing risk of renal impairment.
May interfere with serological assays and diagnostic blood tests due to passively acquired antibodies leading to false positives or negatives.
No significant interactions documented with commonly used antibiotics or antivirals, but clinical monitoring is advised.
Concurrent use with antiplatelet or anticoagulant agents requires careful monitoring due to altered clotting risk.
Reduced immunogenicity of vaccines necessitates communication with healthcare providers regarding timing of immunizations.
Potential additive immunomodulatory effects with other immunosuppressive agents but clinical significance unknown.
Interaction with other plasma-derived products has not been extensively studied; caution advised.
Herbal supplements and vitamins unlikely to have significant interaction but all regimens should be disclosed to the provider.
No known cytochrome P450 mediated drug interactions given protein nature of Xembify.
No modification of metabolism of small-molecule drugs expected due to protein-based mechanism.
Administration timing should be coordinated with live vaccine schedules to optimize efficacy.
Patients should inform all healthcare providers about Xembify use to avoid inadvertent interactions.
Report any unusual symptoms suggestive of interactions such as enhanced bleeding or infection.

Preparations Of The Drug

Sterile, ready-to-use 20% solution of human immune globulin protein for subcutaneous infusion.
Purity of ≥98% IgG with sub-class distribution comparable to normal human serum.
Formulated with inactive ingredients including 0.16 M to 0.26 M glycine and 10 to 40 mcg/mL polysorbate 80 for stability.
pH adjusted between 4.1 and 4.8 to optimize protein stability and minimize irritation.
Preservative-free formulation, minimizing risk of hypersensitivity reactions.
Manufactured by Grifols Therapeutics LLC utilizing cold ethanol fractionation, caprylate precipitation, filtration, and anion-exchange chromatography for purification.
Supplied in vials or prefilled infusion devices compatible with subcutaneous infusion pumps.
Not made with natural rubber latex to reduce risk of latex allergy.
Storage requires refrigeration; stable at room temperature for up to 6 months after removal from refrigeration.
Do not freeze or use past expiration date to ensure potency and safety.
Provided with detailed instructions and training materials for self-administration in outpatient settings.
Appearance is a clear to slightly opalescent solution without particulate matter.
Each milliliter contains approximately 200 mg of IgG protein.
Batch-to-batch viral safety ensured by rigorous plasma donor screening and validated inactivation/removal procedures.
Packaging designed to maintain sterility and prevent contamination during handling.